The effect of the drug Trazodone on motor symptoms of Parkinson's Disease.

Not Applicable

Recruiting

• Conditions: Parkinson Disease

• Registration Number: RBR-4b32m3
• Lead Sponsor: niversidade Federal da Integração Latino-Americana do Brasil (UNILA).

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-08-26
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Individuals with PD clinically diagnosed according to the London Brain Bank criteria. Individuals who voluntarily agree with the procedures and information of the Free and Informed Consent Form. Have cognitive function that allows the understanding of past information by the researcher during the tests (Mini Mental State Examination). Do not present conditions that hinder or impede the movement of the upper limbs, such as: surgeries in the last 12 months; musculotendinosus injuries; fractures; use of prostheses or prostheses; other associated neurological or neurodegenerative conditions; etc. Individuals classified in phase 3 of the Hoeh and Yahr scale.

Exclusion Criteria

Withdrawal from participation in the research. Incomplete completion of the instruments. Individuals with treatment abandonment. Patients with symptoms of parkinsonism induced by exogenous intoxication, infectious, vascular, metabolic, genetic causes, other degenerative diseases or by drugs - such as dopaminergic receptor blockers, anticholinesterases, anticonvulsants, antiarrhythmics, reserpine, tetrabenazine, alfamethyldopa, lithium and fluoxetine. Patients who do not want to stop using monoamine oxidase (MAO) inhibitor drugs. Patients who do not interrupt the use of monoamine oxity (MAO) inhibitor drugs in 15 days before the start of the survey. MAO inhibitors are considered, among others, the following medications: Phenelzine; Iproniazid; Isocarboxazide; Harmalina; Nialamide; Pargyline; Selegiline; Toloxatone; Tranilcipromina. Patients who need to use the linezolid antibiotic, digoxin or phenytoin during the experiment. Diabetic patients or patients with other chronic diseases. Individuals with cardiac disorders or in the recovery phase of an acute myocardial infarction . Patients with reports of psychological disorders such as schizophrenia or bipolar disorder. Patients with renal or hepatic impairment. Pregnant or lactating patients. Patients who have changed the treatment of PD in the past 03 months.

Study & Design

• Study Type: Intervention
• Study Design: Not specified